Compare RYZ & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | SGP |
|---|---|---|
| Founded | 1842 | 2019 |
| Country | United States | United States |
| Employees | 4300 | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 932.9M |
| IPO Year | 2014 | N/A |
| Metric | RYZ | SGP |
|---|---|---|
| Price | $20.74 | $25.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 459.6K | 93.8K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.34 | $24.71 |
| 52 Week High | $27.72 | $30.56 |
| Indicator | RYZ | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 13.90 | 48.38 |
| Support Level | N/A | $25.66 |
| Resistance Level | N/A | $29.83 |
| Average True Range (ATR) | 0.97 | 1.63 |
| MACD | -0.36 | -0.13 |
| Stochastic Oscillator | 17.35 | 27.89 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.